Abstract
121

Methods
122
Ethical clearance was obtained by ANSM (n°IDRCB 2010-A00282-37) and by the committee for the 123 protection of individuals. Written and signed informed consent of all subjects was obtained.
124
The Department of Infectious Diseases of the Hospital of Fort de France started the "DAG" Study in
125
June 2010. This is a descriptive and prognostic study of dengue fever in the French West Indies and 126 French Guiana, based on a hospital cohort of children and adults with suspected dengue fever. The 127 main objective of this study was to define the predictive factors of severe dengue disease. Following 128 the CHIKV introduction in La Martinique, inclusion criteria of the DAG study were extended also to 129 chikungunya cases, with a monitoring adjustment (including a wide description of rheumatic 130 disorders specific to chikungunya disease). In May 2014, the "DAG" study became the "DAG2" study, 131 with a cohort composed of two groups: the dengue group and the chikungunya group. This study is 132 registered on clinicaltrials.gov (NCT01099852). The DAG2 study is still ongoing (the duration of the 133 follow-up is 36 months), and this analysis was conducted at 12 months' follow-up.
134
At the beginning of 2016, the DAG2 cohort was extended to other arbovirosis (including the Zika 135 virus), which has been renamed "the CARBO cohort".
136
This study was proposed to the departments of the Hospital of Fort de France which were likely to 137 receive patients infected by the CHIKV (the emergency department and department of infectious 138 diseases). Therefore, the cohort of patients was ambulatory and reflected so the global population 139 from Martinique affected during the epidemic.
141
Study population 142 For this study, patient inclusion was conducted from December 19, 2013, to December 4, 2014.
143 Inclusion criteria were: age > 16 years old, ability to accept and sign informed consent, positive blood 144 CHIKV qRT-PCR, and onset of symptoms ≤7 days.
145
Data collection and follow-up 146 The DAG questionnaire was adapted to the purpose of our study. Data at the acute stage were 147 collected at the initial visit, and if timely possible at day 3 after the onset of symptoms, between day 148 5 and 7, and between day 8 and 10 including : sociodemographic data, comorbidities and clinical 149 characteristics at baseline (headache, arthralgia myalgia, fever, rash, fatigue, etc.), impact on quality (Table 2) . Biologically, the increase of urea (OR 1.33, 246 95% CI, 1.0.5-1.70, p=0.02) was significantly associated with evolving CHIKC+. No comorbidity 247 (cardiovascular or rheumatologic diseases) was found to be a risk factor for being CHIKC+ (S1 Table   248 and Table 1 ). Impact on quality of life as measured by the EQ5D score at the acute phase was not 249 significantly different between patients in the CHIKC-and CHIKC+ groups (S1 Table) . 
344
One of the strengths of our study was the early inclusion and the prospective follow-up at the 345 epicenter of the epidemic. Moreover, patients were examined physically by a clinician investigator at 346 disease onset and at M3 to monitor clinical manifestations. This objective assessment of symptoms 347 has probably prevented an overestimation of symptoms by the patients; however, some data are 348 subjective as the joint pain assessment.
349
This study, however, has some limitations. First, the phone interview at M6 and M12 could have 350 contributed to a declarative bias. On the other hand, phone calls limit the rate of lost-to-follow-up.
351
The plasma viral load in CHIKC+ and CHIKC-patients might be a track to explore using the biobank 352 of the cohort, together with other immunological and virological investigations. 
